OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TALK$5.1959

Talkspace Inc

Healthcare Facilities & ServicesVerified

Talkspace maintains a strong liquidity position with $37.35 million in cash and equivalents, supported by a current ratio of 6.38, indicating robust short-term financial health. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. However, free cash flow is negative at -$248,000, suggesting operational cash flow is insufficient to cover capital expenditures of -$10.64 million. Profitability metrics show a return on equity (ROE) of 6.66% and a return on assets (ROA) of 5.78%, both below the industry median for healthcare services. The company's net income of $7.79 million is modest relative to its revenue of $228.87 million, indicating thin profit margins. Gross profit of $98.35 million represents 43% of revenue, which is in line with industry norms but leaves little room for operating expenses. Talkspace's revenue is concentrated in the United States, with no disclosed international segments. The company's business model is heavily dependent on digital subscriptions and insurance partnerships, which exposes it to regulatory and reimbursement risk. No material geographic diversification is evident in the financial data. Outlook for the current fiscal year shows a modest growth trajectory, with no significant revenue acceleration expected. The company's price-to-earnings ratio of 111.27 and enterprise value-to-revenue ratio of 3.63 suggest a premium valuation relative to earnings but a moderate multiple on revenue. Analysts have assigned a mean price target of $6.12, implying a 18% upside from the current market price of $5.19. Risk factors include the absence of long-term debt, which reduces financial leverage but also limits growth capital. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. However, the negative free cash flow and high capital expenditures may pressure liquidity in the near term. Recent events include the publication of Q4 2023 financial results, which showed a slight improvement in operating income to $3.15 million. No major regulatory or legal developments were disclosed in the latest filings. The company continues to focus on expanding its therapist network and improving user engagement.

30-day price · TALK+0.02 (+0.4%)
Low$5.16High$5.20Close$5.20As of22 May, 00:00 UTC
Profile
CompanyTalkspace Inc
TickerTALK.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Talkspace Inc provides online mental health services, connecting users with licensed therapists through a digital platform, generating revenue primarily through subscription fees and insurance reimbursements.

Classification. Talkspace is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

Talkspace maintains a strong liquidity position with $37.35 million in cash and equivalents, supported by a current ratio of 6.38, indicating robust short-term financial health. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. However, free cash flow is negative at -$248,000, suggesting operational cash flow is insufficient to cover capital expenditures of -$10.64 million. Profitability metrics show a return on equity (ROE) of 6.66% and a return on assets (ROA) of 5.78%, both below the industry median for healthcare services. The company's net income of $7.79 million is modest relative to its revenue of $228.87 million, indicating thin profit margins. Gross profit of $98.35 million represents 43% of revenue, which is in line with industry norms but leaves little room for operating expenses. Talkspace's revenue is concentrated in the United States, with no disclosed international segments. The company's business model is heavily dependent on digital subscriptions and insurance partnerships, which exposes it to regulatory and reimbursement risk. No material geographic diversification is evident in the financial data. Outlook for the current fiscal year shows a modest growth trajectory, with no significant revenue acceleration expected. The company's price-to-earnings ratio of 111.27 and enterprise value-to-revenue ratio of 3.63 suggest a premium valuation relative to earnings but a moderate multiple on revenue. Analysts have assigned a mean price target of $6.12, implying a 18% upside from the current market price of $5.19. Risk factors include the absence of long-term debt, which reduces financial leverage but also limits growth capital. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. However, the negative free cash flow and high capital expenditures may pressure liquidity in the near term. Recent events include the publication of Q4 2023 financial results, which showed a slight improvement in operating income to $3.15 million. No major regulatory or legal developments were disclosed in the latest filings. The company continues to focus on expanding its therapist network and improving user engagement.
Key takeaways
  • Talkspace has a strong liquidity position with $37.35 million in cash and a current ratio of 6.38.
  • The company's ROE of 6.66% and ROA of 5.78% are below industry medians, indicating moderate profitability.
  • Revenue is concentrated in the U.S., with no material international exposure.
  • The stock is trading at a high P/E of 111.27 but a moderate EV/Revenue of 3.63.
  • No immediate liquidity or dilution risks are present, but negative free cash flow may pressure operations.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$228.9M
Gross profit$98.3M
Operating income$3.2M
Net income$7.8M
R&D
SG&A
D&A
SBC
Operating cash flow$8.5M
CapEx-$10.6M
Free cash flow-$248.0k
Total assets$134.9M
Total liabilities$17.8M
Total equity$117.0M
Cash & equivalents$37.4M
Long-term debt$0.00
Valuation
Market price$5.19
Market cap$867.1M
Enterprise value$829.8M
P/E111.3
Reported non-GAAP P/E
EV/Revenue3.6
EV/Op income263.2
EV/OCF97.2
P/B7.4
P/Tangible book7.4
Tangible book$117.0M
Net cash$37.4M
Current ratio6.4
Debt/Equity0.0
ROA5.8%
ROE6.7%
Cash conversion1.1%
CapEx/Revenue-4.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricTALKActivity
Op margin1.4%7.7% medp25 -2.4% · p75 15.5%below median
Net margin3.4%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin43.0%45.5% medp25 31.1% · p75 62.9%below median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-4.7%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity0.0%25.0% medp25 3.8% · p75 63.3%bottom quartile
Observations
IR observations
Mean price target6.12 USD
Median price target5.62 USD
High price target9.00 USD
Low price target5.25 USD
Mean recommendation2.75 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count6.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.14 USD
Last actual EPS0.04 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 23:45 UTC#40eab8b9
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 15:50 UTCJob: a32dce26